Pharma BD Deal Intelligence
Mirum acquired Bluejay Therapeutics for $250M cash and $370M in Mirum stock ($620M upfront) plus up to $200M in sales-based milestones (total up to $820M), gaining worldwide rights to brelovitug (BJT-778), a Phase 3 fully human IgG1 monoclonal antibody with Breakthrough Therapy (FDA) and PRIME (EMA) designations for chronic hepatitis delta virus (HDV). The acquisition CLOSED January 23, 2026. On April 27, 2026, Mirum reported that the Phase 2b portion of the registrational AZURE-1 study met its primary composite endpoint (virologic response + ALT normalization) and was well tolerated, materially de-risking the program. Pivotal AZURE 24-week topline data remain expected 2H 2026 with a BLA targeted for 2027.